Level C· Early human research exploring benefitsCohort StudyEurope PMCOpen access

Joint analysis of left ventricular expression and circulating plasma levels of Omentin after myocardial ischemia

Saddic LA., Nicoloro SM., Gupta OT., Czech MP., Gorham J., Shernan SK.

Cohort Study with a reported sample of 140 on Cardiovascular Disease, published in Cardiovasc Diabetol (2017) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Cohort Study
Journal
Cardiovasc Diabetol (2017)
Reported sample size
140
Source database
Europe PMC
PMID
28687077
PMCID
PMC5501278
DOI
10.1186/s12933-017-0567-x
NCT
NCT00985049
Citations
13

Abstract (original English)

Background Omentin-1, also known as Intelectin-1 (ITLN1), is an adipokine with plasma levels associated with diabetes, obesity, and coronary artery disease. Recent studies suggest that ITLN1 can mitigate myocardial ischemic injury but the expression of ITLN1 in the heart itself has not been well characterized. The purpose of this study is to discern the relationship between the expression pattern of ITLN1 RNA in the human heart and the level of circulating ITLN1 protein in plasma from the same patients following myocardial ischemia. Methods A large cohort of patients (n = 140) undergoing elective cardiac surgery for aortic valve replacement were enrolled in this study. Plasma and left ventricular biopsy samples were taken at the beginning of cardiopulmonary bypass and after an average of 82 min of ischemic cross clamp time. The localization of ITLN1 in epicardial adipose tissue (EAT) was also further characterized with immunoassays and cell fate transition studies. Results mRNA expression of ITLN1 decreases in left ventricular tissue after acute ischemia in human patients (mean difference 280.48, p = 0.001) whereas plasma protein levels of ITLN1 increase (mean difference 5.24, p Conclusions Myocardial injury leads to a decrease in ITLN1 expression in the heart and a corresponding increase in plasma levels. These changes may in part be due to an epithelial to mesenchymal transit

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Aortic ValvePericardiumAdipose TissueHumansMyocardial IschemiaLectinsCytokinesAgedAged, 80 and overMiddle Aged

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research